Work

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Year: 2020

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2020-139705

Authors: Naval Daver, Jessica K. Altman, Joseph Maly, Mark Levis, Ellen Ritchie, Mark Litzow, James K. McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Wan-Jen Hong, Bo Tong, Qin Qin, Kimberley Dilley, Alexander E. Perl

Institutions: The University of Texas MD Anderson Cancer Center, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Norton Healthcare, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Mayo Clinic, Hackensack Meridian Health, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, Los Angeles, University of Miami, Sylvester Comprehensive Cancer Center, Astellas Pharma (United States), Genentech, AbbVie (United States), Abramson Cancer Center, University of Pennsylvania

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3094796233

FWCI: 3.404

Cites:

Cited by: 27

Related to: 10